Blood cancer patients get continued access to promising drug in new study

NCT ID NCT06465433

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study provides ongoing treatment with tafasitamab for up to 25 adults with blood cancers who are already benefiting from the drug in an earlier study. The main goal is to monitor safety and side effects over time. Participants must be tolerating the treatment well and have stable or improved disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Clinica Universitad de Navarra
COMPLETED

Pamplona, 31008, Spain
Gazi University Hospital Gazi University Faculty of Medicine
RECRUITING

Ankara, 06500, Turkey (Türkiye)
Hospital S.M. Terni University of Perugia
COMPLETED

Terni, 05100, Italy
Petz Aladar County Teaching Hospital
RECRUITING

Győr, 09023, Hungary
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.